Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE) from its SEC filings: 2025 revenue $0, free cash flow -$169.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $0 |
| Net income | -$155.2 million |
| Free cash flow | -$169.3 million |
| Cash | $162.0 million |
| Share count, 1 year | +46% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.